Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (H5N1_scATAC-seq)

ABSTRACT: Human subjects were vaccinated with adjuvanted (AS03) or unadjuvanted pre-pandemic influenza vaccines H5N1 at day 0 and d21. We then used scATAC-seq to construct the single-cell landscape of the innate immune response to those vaccines at the epigenomic level. PBMCs from vaccinated individuals were isolated at day 0, 21, and 42, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell chromatin accessibility profiling.

ORGANISM(S): Homo sapiens

PROVIDER: GSE165904 | GEO | 2021/06/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (H5N1_scRNA-seq)

Project description:Human subjects were vaccinated with adjuvanted (AS03) or unadjuvanted pre-pandemic influenza vaccines H5N1 at day 0 and d21. We then used scRNA-seq to construct the single-cell landscape of the innate immune response to those vaccines at the transcriptional level. PBMCs from vaccinated individuals were isolated at day 0, 21, and 42, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell gene expression profiling.

2021-06-25 | GSE165903 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

Project description:Human subjects were vaccinated with seasonal influenza vaccine at day 0 (TIV, 2014-2015). A subgroup of subjects (abx) received an additional oral antibiotic regimen, consisting of neomycin, vancomycin, and metronidazole, between days -3 and 1. CD14+ monocytes were isolated from PBMCs of vaccinated subjects (2 antibiotic treated, 3 controls) at day 0 and 30 using FACS. RNA-seq was used to analyze the transcriptional landscape in these cells.

2021-06-25 | GSE166063 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans [ATAC-seq]

Project description:Human subjects were vaccinated with seasonal influenza vaccine at day 0 (TIV, 2014-2015). A subgroup of subjects (abx) received an additional oral antibiotic regimen, consisting of neomycin, vancomycin, and metronidazole, between days -3 and 1. CD14+ monocytes, mDCs, and pDCs were isolated from PBMCs of vaccinated subjects (3 antibiotic treated, 5 controls) at day -21 (BL), 0 and 30 using FACS. ATAC-seq was used to analyze the chromatin accessibility landscape in these cells.

2021-06-25 | GSE166180 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (TIV_scATAC-seq)

Project description:Human subjects were vaccinated with seasonal influenza vaccine (TIV, 2014-2015). We then used scATAC-seq to construct the single-cell landscape of the innate immune response to TIV at the epigenomic level. PBMCs from vaccinated individuals were isolated at day 0, 1, and 30, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell chromatin accessibility profiling.

2021-06-25 | GSE165906 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (TIV_scRNA-seq)

Project description:Human subjects were vaccinated with seasonal influenza vaccine (TIV, 2014-2015). We then used scRNA-seq to constructed the single-cell landscape of the innate immune response to TIV at the transcriptional level. PBMCs from vaccinated individuals were isolated at day 0, 1, and 30, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell gene expression profiling.

2021-06-25 | GSE165905 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_1_iga)

Project description:Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and hetero-subtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. Adjuvanted vaccine was also associated with the elicitation of stalk directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.

2022-07-01 | GSE202380 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_3_igg)

2022-07-01 | GSE202388 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_3_iga)

2022-07-01 | GSE202387 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_2_igg)

2022-07-01 | GSE202385 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_2_iga)

2022-07-01 | GSE202383 | GEO